Active ingredient description

Auranofin is an orally available compound, used to treat rheumatoid arthritis, with anti-inflammatory activities. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes such as thioredoxin reductase (TrxR). The thiol ligand contained in auranofin has a high affinity for thiol and selenol groups, to which it forms stable, and irreversible, adducts. Redox enzymes such as TrxR are essential to many cellular processes, particularly in maintaining the intracellular levels of reactive oxygen species (ROS).

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01C Specific antirheumatic agents → M01CB Gold preparations
Discover more medicines within M01CB03


Auranofin is the active ingredient of these drugs:


Australia Canada South Africa United States

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₀H₃₄AuO₉PS
Molecular mass: 678.484 g/mol

3D molecular structure

3D representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 34031-32-8
DrugBank Drug: DB00995
KEGG Drug: D00237
PubChem Compound: 24199313
RxNorm Ingredient: 1227
SNOMED-CT Concept: 387100001
Auranofin (substance)
UNII Identifier: 3H04W2810V